Incidensen af forsinket heling af hoftefrakturer var sammenlignelig mellem Aclasta (34 [3, 2%]) og placebo (29 [2, 7%]).
The incidence of delayed hip fracture healing was comparable between Aclasta (34 [3.2%]) and placebo (29 [2.7%]).